These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 22469288)
1. De novo daptomycin-nonsusceptible enterococcal infections. Kelesidis T; Humphries R; Uslan DZ; Pegues D Emerg Infect Dis; 2012 Apr; 18(4):674-6. PubMed ID: 22469288 [TBL] [Abstract][Full Text] [Related]
2. Daptomycin: A viable therapeutic option for vancomycin-resistant enterococcal urinary-tract infections in Indian medical settings? Mohan B; Garg S; Appannanavar SB; Taneja N Indian J Med Microbiol; 2016; 34(3):398-9. PubMed ID: 27514977 [No Abstract] [Full Text] [Related]
3. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Casapao AM; Kullar R; Davis SL; Levine DP; Zhao JJ; Potoski BA; Goff DA; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ Antimicrob Agents Chemother; 2013 Sep; 57(9):4190-6. PubMed ID: 23774437 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of enterococci to daptomycin is dependent upon testing methodology. Bryant KA; Roberts AL; Rupp ME; Anderson JR; Lyden ER; Fey PD; Van Schooneveld TC Diagn Microbiol Infect Dis; 2013 Aug; 76(4):497-501. PubMed ID: 23719086 [TBL] [Abstract][Full Text] [Related]
5. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Mohr JF; Friedrich LV; Yankelev S; Lamp KC Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165 [TBL] [Abstract][Full Text] [Related]
6. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Alder J; Li T; Yu D; Morton L; Silverman J; Zhang XX; Critchley I; Thorne G Antimicrob Agents Chemother; 2003 Nov; 47(11):3561-6. PubMed ID: 14576118 [TBL] [Abstract][Full Text] [Related]
7. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168 [No Abstract] [Full Text] [Related]
8. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey. Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140 [No Abstract] [Full Text] [Related]
9. Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility. Wang G; Kamalakaran S; Dhand A; Huang W; Ojaimi C; Zhuge J; Yee LL; Mayigowda P; Surendraiah PK; Dimitrova N; Fallon JT Antimicrob Agents Chemother; 2014 Aug; 58(8):4848-54. PubMed ID: 24913170 [TBL] [Abstract][Full Text] [Related]
10. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Kelesidis T; Humphries R; Uslan DZ; Pegues DA Clin Infect Dis; 2011 Jan; 52(2):228-34. PubMed ID: 21288849 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin for the treatment of vancomycin-resistant enterococcal infections. Grim SA; Hong I; Freeman J; Edwards C; Clark NM J Antimicrob Chemother; 2009 Feb; 63(2):414-6. PubMed ID: 19015143 [No Abstract] [Full Text] [Related]
12. Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin. Fraher MH; Corcoran GD; Creagh S; Feeney E J Hosp Infect; 2007 Apr; 65(4):376-8. PubMed ID: 17316896 [No Abstract] [Full Text] [Related]
13. Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model. Kidd JM; Abdelraouf K; Asempa TE; Humphries RM; Nicolau DP Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012755 [TBL] [Abstract][Full Text] [Related]
16. Emergence of daptomycin-resistant VRE: experience of a single institution. Kamboj M; Cohen N; Gilhuley K; Babady NE; Seo SK; Sepkowitz KA Infect Control Hosp Epidemiol; 2011 Apr; 32(4):391-4. PubMed ID: 21460492 [TBL] [Abstract][Full Text] [Related]
17. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Cunha BA; Mickail N; Eisenstein L Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808 [TBL] [Abstract][Full Text] [Related]
18. De novo daptomycin nonsusceptibility in a clinical isolate. Lesho EP; Wortmann GW; Craft D; Moran KA J Clin Microbiol; 2006 Feb; 44(2):673. PubMed ID: 16455945 [No Abstract] [Full Text] [Related]
19. Failure of daptomycin β-Lactam combination therapy to prevent resistance emergence in Enterococcus faecium. Menon V; Davis R; Shackel N; Espedido BA; Beukers AG; Jensen SO; van Hal SJ Diagn Microbiol Infect Dis; 2018 Feb; 90(2):120-122. PubMed ID: 29195768 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. Judge T; Pogue JM; Marchaim D; Ho K; Kamatam S; Parveen S; Tiwari N; Nanjireddy P; Bheemreddy S; Biedron C; Reddy SM; Khammam V; Chalana IK; Tumma RS; Collins V; Yousuf A; Lephart PR; Martin ET; Rybak MJ; Kaye KS; Hayakawa K Infect Control Hosp Epidemiol; 2012 Dec; 33(12):1250-4. PubMed ID: 23143365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]